These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 27194006)

  • 1. Development and evaluation of two subunit vaccine candidates containing antigens of hepatitis E virus, rotavirus, and astrovirus.
    Xia M; Wei C; Wang L; Cao D; Meng XJ; Jiang X; Tan M
    Sci Rep; 2016 May; 6():25735. PubMed ID: 27194006
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A trivalent vaccine candidate against hepatitis E virus, norovirus, and astrovirus.
    Xia M; Wei C; Wang L; Cao D; Meng XJ; Jiang X; Tan M
    Vaccine; 2016 Feb; 34(7):905-13. PubMed ID: 26778421
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A dual vaccine candidate against norovirus and hepatitis E virus.
    Wang L; Cao D; Wei C; Meng XJ; Jiang X; Tan M
    Vaccine; 2014 Jan; 32(4):445-52. PubMed ID: 24291540
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rectal immunization with rotavirus virus-like particles induces systemic and mucosal humoral immune responses and protects mice against rotavirus infection.
    Parez N; Fourgeux C; Mohamed A; Dubuquoy C; Pillot M; Dehee A; Charpilienne A; Poncet D; Schwartz-Cornil I; Garbarg-Chenon A
    J Virol; 2006 Feb; 80(4):1752-61. PubMed ID: 16439532
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Branched-linear and agglomerate protein polymers as vaccine platforms.
    Wang L; Xia M; Huang P; Fang H; Cao D; Meng XJ; McNeal M; Jiang X; Tan M
    Biomaterials; 2014 Sep; 35(29):8427-38. PubMed ID: 24985736
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunization of Mice by Rotavirus NSP4-VP6 Fusion Protein Elicited Stronger Responses Compared to VP6 Alone.
    Afchangi A; Arashkia A; Shahosseini Z; Jalilvand S; Marashi SM; Roohvand F; Mohajel N; Shoja Z
    Viral Immunol; 2018 Apr; 31(3):233-241. PubMed ID: 29185875
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immune responses elicited against rotavirus middle layer protein VP6 inhibit viral replication in vitro and in vivo.
    Lappalainen S; Pastor AR; Tamminen K; López-Guerrero V; Esquivel-Guadarrama F; Palomares LA; Vesikari T; Blazevic V
    Hum Vaccin Immunother; 2014; 10(7):2039-47. PubMed ID: 25424814
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunogenicity and protective efficacy of rotavirus VP8* fused to cholera toxin B subunit in a mouse model.
    Xue M; Yu L; Jia L; Li Y; Zeng Y; Li T; Ge S; Xia N
    Hum Vaccin Immunother; 2016 Nov; 12(11):2959-2968. PubMed ID: 27435429
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Specific memory B cell response and participation of CD4
    Kulkarni SP; Thanapati S; Arankalle VA; Tripathy AS
    Vaccine; 2016 Nov; 34(48):5895-5902. PubMed ID: 27997340
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rotavirus capsid VP6 protein acts as an adjuvant in vivo for norovirus virus-like particles in a combination vaccine.
    Blazevic V; Malm M; Arinobu D; Lappalainen S; Vesikari T
    Hum Vaccin Immunother; 2016 Mar; 12(3):740-8. PubMed ID: 26467630
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Characterization and protective efficacy in an animal model of a novel truncated rotavirus VP8 subunit parenteral vaccine candidate.
    Xue M; Yu L; Che Y; Lin H; Zeng Y; Fang M; Li T; Ge S; Xia N
    Vaccine; 2015 May; 33(22):2606-13. PubMed ID: 25882173
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bioengineered Norovirus S
    Xia M; Huang P; Sun C; Han L; Vago FS; Li K; Zhong W; Jiang W; Klassen JS; Jiang X; Tan M
    ACS Nano; 2018 Nov; 12(11):10665-10682. PubMed ID: 30234973
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Design and testing of a highly conserved human rotavirus VP8* immunogenic peptide with potential for vaccine development.
    Mohanty E; Dehury B; Satapathy AK; Dwibedi B
    J Biotechnol; 2018 Sep; 281():48-60. PubMed ID: 29886031
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prophylactic Herpes Simplex Virus 2 (HSV-2) Vaccines Adjuvanted with Stable Emulsion and Toll-Like Receptor 9 Agonist Induce a Robust HSV-2-Specific Cell-Mediated Immune Response, Protect against Symptomatic Disease, and Reduce the Latent Viral Reservoir.
    Hensel MT; Marshall JD; Dorwart MR; Heeke DS; Rao E; Tummala P; Yu L; Cohen GH; Eisenberg RJ; Sloan DD
    J Virol; 2017 May; 91(9):. PubMed ID: 28228587
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety and immunogenicity of a parenterally administered rotavirus VP8 subunit vaccine in healthy adults.
    Fix AD; Harro C; McNeal M; Dally L; Flores J; Robertson G; Boslego JW; Cryz S
    Vaccine; 2015 Jul; 33(31):3766-72. PubMed ID: 26065919
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Protection against live rotavirus challenge in mice induced by parenteral and mucosal delivery of VP6 subunit rotavirus vaccine.
    Lappalainen S; Pastor AR; Malm M; López-Guerrero V; Esquivel-Guadarrama F; Palomares LA; Vesikari T; Blazevic V
    Arch Virol; 2015 Aug; 160(8):2075-8. PubMed ID: 26016444
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Recombinant Subunit Rotavirus Trivalent Vaccine Candidate: Physicochemical Comparisons and Stability Evaluations of Three Protein Antigens.
    Agarwal S; Hickey JM; Sahni N; Toth RT; Robertson GA; Sitrin R; Cryz S; Joshi SB; Volkin DB
    J Pharm Sci; 2020 Jan; 109(1):380-393. PubMed ID: 31400347
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immune response and protective efficacy of the S particle presented rotavirus VP8* vaccine in mice.
    Xia M; Huang P; Jiang X; Tan M
    Vaccine; 2019 Jul; 37(30):4103-4110. PubMed ID: 31201052
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Polyvalent complexes for vaccine development.
    Wang L; Huang P; Fang H; Xia M; Zhong W; McNeal MM; Jiang X; Tan M
    Biomaterials; 2013 Jun; 34(18):4480-92. PubMed ID: 23498893
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Distribution and phenotype of murine rotavirus-specific B cells induced by intranasal immunization with 2/6 virus-like particles.
    Ogier A; Franco MA; Charpilienne A; Cohen J; Pothier P; Kohli E
    Eur J Immunol; 2005 Jul; 35(7):2122-30. PubMed ID: 15948217
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.